Pathstone Holdings
TAK icon

Pathstone Holdings’s Takeda Pharmaceutical TAK Stock Holding History

Pathstone Holdings’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Sell
239,306
-1,987
-0.8% -$32.9K 0.01% 776
2026
Q1 		$4.47M Buy
241,293
+24,916
+12% +$437K 0.02% 612
2025
Q4 		$3.37M Sell
216,377
-21,961
-9% -$314K 0.01% 745
2025
Q3 		$3.49M Buy
238,338
+16,486
+7% +$245K 0.01% 717
2025
Q2 		$3.44M Buy
221,852
+7,093
+3% +$105K 0.01% 703
2025
Q1 		$3.19M Sell
214,759
-101,553
-32% -$1.42M 0.01% 740
2024
Q4 		$4.19M Sell
316,312
-114,364
-27% -$1.57M 0.02% 613
2024
Q3 		$6.12M Buy
430,676
+4,280
+1% +$60.7K 0.03% 487
2024
Q2 		$5.52M Sell
426,396
-5,787
-1% -$76.6K 0.02% 490
2024
Q1 		$6M Buy
432,183
+106,237
+33% +$1.55M 0.03% 452
2023
Q4 		$4.65M Buy
+325,946
New +$4.62M 0.03% 453

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Pathstone Holdings's TAK Position: Q2 2026 in Review

Pathstone Holdings reduced its Takeda Pharmaceutical (TAK) stake by 0.82% in Q2 2026, selling an estimated $32.9K and leaving 239,306 shares worth $3.84M. The position accounts for 0.01% of the portfolio, ranked #776.

Pathstone Holdings first reported a position in TAK in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.12M in Q3 2024. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Pathstone Holdings held 239,306 shares of Takeda Pharmaceutical worth $3.84M as of Q2 2026.
  • Pathstone Holdings sold 1,987 Takeda Pharmaceutical shares in Q2 2026, an estimated $32.9K.
  • Takeda Pharmaceutical made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #776 holding.
  • Pathstone Holdings first reported a position in Takeda Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Takeda Pharmaceutical position peaked at $6.12M in Q3 2024.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.